| |
| |
|
| Insider
Information: |
Chevallard Daniel R. |
| Relationship: |
CFO and COO |
| City: |
San Diego |
| State: |
CA |
| |
|
| Insider
Summary: |
|
|
|
|
Companies Owned : |
2 |
|
| Direct
Shares |
180,176 |
|
|
Indirect Shares
|
0 |
|
|
| Direct
Value |
$249,845 |
|
|
|
Indirect Value
|
$0 |
|
|
| Total
Shares |
180,176 |
|
|
| Total
Value |
$249,845 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
|
Total
Filings :
|
0
|
9
|
|
Stock
price went up :
|
0
|
3
|
| Stock
price went down : |
0
|
6
|
| |
|
|
|
Gain/Loss Ratio : |
0.0
|
0.0
|
| Percentage
Gain/Loss : |
0.0%
|
 -202.7%
|
| |
|
|
|
|
|
Holdings
:
| Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold  |
 |
Regulus Therapeutics Inc. |
RGLS |
Chief Financial Officer |
2019-07-01 |
77,870 |
|
0 |
Premium* |
|
|
Viracta Therapeutics Ord Shs |
VIRX |
CFO and COO |
2024-02-27 |
102,306 |
|
0 |
Premium* |
|
|
|
|
|
|
|
|
|
|
|
Records found :
25 |
Free Registration Required For Full Results. Limit: 25
|
 |
Download |
Page 1 of 1
|
| Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
| VIRX |
Viracta Therapeutics Ord ... |
CFO and COO |
• – – |
2024-02-27 |
4 |
S |
$0.73 |
$2,493 |
D/D |
(3,405) |
102,306 |
0 |
- |
|
| VIRX |
Viracta Therapeutics Ord ... |
CFO and COO |
• – – |
2024-02-25 |
4 |
OE |
$0.00 |
$0 |
D/D |
6,889 |
105,711 |
0 |
- |
|
| VIRX |
Viracta Therapeutics Ord ... |
CFO and COO |
• – – |
2023-11-28 |
4 |
S |
$0.50 |
$1,860 |
D/D |
(3,720) |
98,822 |
0 |
% |
|
| VIRX |
Viracta Therapeutics Ord ... |
CFO and COO |
• – – |
2023-11-25 |
4 |
OE |
$0.00 |
$0 |
D/D |
6,889 |
102,542 |
0 |
- |
|
| VIRX |
Viracta Therapeutics Ord ... |
CFO and COO |
• – – |
2023-08-28 |
4 |
S |
$1.45 |
$5,092 |
D/D |
(3,512) |
95,653 |
0 |
% |
|
| VIRX |
Viracta Therapeutics Ord ... |
CFO and COO |
• – – |
2023-08-25 |
4 |
OE |
$0.00 |
$0 |
D/D |
6,888 |
99,165 |
0 |
- |
|
| VIRX |
Viracta Therapeutics Ord ... |
CFO and COO |
• – – |
2023-05-25 |
4 |
OE |
$0.00 |
$0 |
D/D |
6,889 |
95,912 |
0 |
- |
|
| VIRX |
Viracta Therapeutics Ord ... |
CFO and COO |
• – – |
2023-05-25 |
4 |
S |
$1.42 |
$5,160 |
D/D |
(3,635) |
92,277 |
0 |
% |
|
| VIRX |
Viracta Therapeutics Ord ... |
CFO and COO |
• – – |
2023-02-27 |
4 |
S |
$1.68 |
$6,051 |
D/D |
(3,599) |
89,023 |
0 |
% |
|
| VIRX |
Viracta Therapeutics Ord ... |
CFO and COO |
• – – |
2023-02-25 |
4 |
OE |
$0.00 |
$0 |
D/D |
6,889 |
92,622 |
0 |
- |
|
| VIRX |
Viracta Therapeutics Ord ... |
CFO and COO |
• – – |
2022-11-28 |
4 |
S |
$2.72 |
$9,606 |
D/D |
(3,532) |
85,733 |
0 |
% |
|
| VIRX |
Viracta Therapeutics Ord ... |
CFO and COO |
• – – |
2022-11-25 |
4 |
OE |
$0.00 |
$0 |
D/D |
6,889 |
89,265 |
0 |
- |
|
| VIRX |
Viracta Therapeutics Ord ... |
CFO and COO |
• – – |
2022-08-26 |
4 |
S |
$4.02 |
$14,679 |
D/D |
(3,655) |
82,376 |
0 |
% |
|
| VIRX |
Viracta Therapeutics Ord ... |
CFO and COO |
• – – |
2022-08-25 |
4 |
OE |
$0.00 |
$0 |
D/D |
6,889 |
86,031 |
0 |
- |
|
| VIRX |
Viracta Therapeutics Ord ... |
CFO and COO |
• – – |
2022-05-26 |
4 |
S |
$1.90 |
$6,836 |
D/D |
(3,596) |
79,142 |
0 |
% |
|
| VIRX |
Viracta Therapeutics Ord ... |
CFO and COO |
• – – |
2022-05-25 |
4 |
OE |
$0.00 |
$0 |
D/D |
6,889 |
82,738 |
0 |
- |
|
| VIRX |
Viracta Therapeutics Ord ... |
CFO and COO |
• – – |
2022-02-28 |
4 |
S |
$2.78 |
$11,112 |
D/D |
(3,998) |
75,849 |
0 |
% |
|
| VIRX |
Viracta Therapeutics Ord ... |
CFO and COO |
• – – |
2022-02-25 |
4 |
OE |
$0.00 |
$0 |
D/D |
6,889 |
79,847 |
0 |
- |
|
| VIRX |
Viracta Therapeutics Ord ... |
CFO and COO |
• – – |
2021-09-28 |
4 |
OE |
$0.90 |
$9,000 |
D/D |
10,000 |
66,760 |
0 |
- |
|
| VIRX |
Viracta Therapeutics Ord ... |
CFO and COO |
• – – |
2021-05-28 |
4 |
OE |
$0.90 |
$10,800 |
D/D |
12,000 |
56,760 |
0 |
- |
|
| VIRX |
Viracta Therapeutics Ord ... |
Chief Executive OfficerOfficer |
• – – |
2021-02-24 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
44,760 |
|
% |
|
| RGLS |
Regulus Therapeutics Inc. |
Chief Financial Officer |
• – – |
2019-07-01 |
4 |
AS |
$1.31 |
$3,500 |
D/D |
(2,669) |
77,870 |
0 |
- |
|
| RGLS |
Regulus Therapeutics Inc. |
Chief Financial Officer |
• – – |
2019-05-15 |
4 |
AS |
$1.41 |
$14,089 |
D/D |
(10,000) |
80,539 |
0 |
- |
|
| RGLS |
Regulus Therapeutics Inc. |
Chief Financial Officer |
• – – |
2019-05-14 |
4 |
A |
$0.00 |
$0 |
D/D |
55,414 |
90,539 |
0 |
- |
|
| RGLS |
Regulus Therapeutics Inc. |
Chief Financial Officer |
• – – |
2019-04-01 |
4 |
AS |
$0.98 |
$3,192 |
D/D |
(3,253) |
9,372 |
0 |
- |
|
25 Records found
|
1
|
Page 1 of 1 |
| |
Free Registration Required For Full Results. Limit: 25
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
